Ema Pharma: Trusted Supplier of Aluminum Seals for Injectable Drugs
When selecting a supplier of aluminum seals for injectable drugs, you are not purchasing a “cosmetic” accessory. You are qualifying a component that supports vial closure integrity, protects the stopper puncture zone, and locks the closure system in its final state after stoppering and capping. EU GMP Annex 1 states that the container closure system for aseptically filled vials is not fully integral until the aluminum cap has been crimped onto the stoppered vial; therefore, the capping step becomes part of the sterility assurance logic.
Ema Pharma (France) specializes in aluminum overseals for injectable pharma applications, offering bulk, Ready-to-Sterilize (RTS) and Ready-to-Use (RTU) finishes, with a quality system aligned with ISO 15378 and the expectations of global fill-finish operations.
1) What aluminum seals really do in an injectable vial system
An aluminum seal (crimp cap/overseal) works with the elastomeric stopper and glass vial to maintain the closure in a defined, stable geometry.
From a functional point of view, aluminum seals contribute to:
● Stopper retention and compression lock-in after crimping (the mechanical condition that supports seal tightness over time).
● Protection of the puncture area (flip-off/push-off designs reduce the risk of soiling and mechanical damage to the stopper’s penetration zone).
● Tamper evidence (opening requires a visible action; features such as scorelines or tear-off designs show first opening).
● Process compatibility with high-speed capping and automated inspection.
A practical way to summarize it: no cap, no maintained compression, no dependable closure state after handling. Training material on aluminum seals makes the same point: after crimping, the “seal” function shifts to the stopper flange-to-vial interface, and the aluminum cap is what keeps the required compression in place.
2) Aluminum seals are not stoppers: scope, risk, and responsibilities
A common sourcing mistake is treating aluminum caps and rubber stoppers as governed by the same rules.
● Elastomeric stoppers are in direct contact with the drug product and fall under pharmacopeial monographs and extractables/leachables programs.
● Aluminum seals do not come into contact with the drug product, but they are still part of the container closure system and influence CCI through crimp quality, stopper compression, and protection of the access area.
Ema Pharma manufactures overseals only (aluminum caps and aluminum/plastic flip-off or push-off designs). It does not manufacture rubber stoppers. Your qualification package should reflect that difference in scope.
3) What regulators and industry standards expect from an aluminum seal supplier
A. EU GMP Annex 1: capping is tied to sterility assurance
Annex 1 (published in Eudralex Volume 4 on August 25, 2022) adds pressure on contamination control strategies and reinforces expectations around container closure of sterile products. It highlights:
● capping should happen as soon as possible after stopper insertion,
● stoppered vials should be protected under Grade A conditions until crimping,
● isolators and RABS are strongly recommended to reduce contamination risk.
This is one driver behind the move from bulk caps toward RTS/RTU formats, especially for lyophilized products.
B. ISO standards: dimensions, materials, and performance tests
Key references that shape aluminum seal requirements include:
● ISO 8362 / ISO 8536 for dimensions, tolerances, and functional requirements (vials and infusion bottles).
● ISO 8872 for aluminum cap general requirements and test methods (materials, sterilization resistance, packaging expectations).
● ISO 10985 for aluminum–plastic combination caps (flip-off / push-off), including opening force test logic.
Defect classification and visual inspection: PDA TR 76
Visible nonconformities are a major topic during incoming inspection and supplier audits. PDA Technical Report 76 was written to provide consistent criteria for visual inspection of elastomeric components and aluminum seals, with standardized defect classification concepts.
For a purchasing and QA team, this matters because it supports:
● clearer defect definitions (critical/major/minor logic),
● aligned inspection language between pharma sites and suppliers,
● less subjective “cosmetic vs functional” debate during deviations.
Ema Pharma is directly connected to TR 76 through participation in the technical report team.
CCI expectations: deterministic methods gain priority
Industry practice and guidance increasingly favor deterministic CCI test methods (helium leak, vacuum decay, laser headspace analysis) rather than legacy probabilistic methods. Training material on CCI lists deterministic and probabilistic technologies and references USP <1207> as a core framework for sterile product package integrity.
For seals, the supplier’s role is indirect: the cap design and manufacturing consistency must support repeatable crimping, which supports consistent closure conditions for the stopper.
4) How to qualify a supplier of aluminum seals for injectable drugs
A strong qualification is not built on brochures. It is built on evidence that the supplier controls the drivers of line performance and patient-risk-linked attributes.
Here is a practical, audit-ready checklist.
A. Quality system and audit readiness
Look for:
● ISO 15378 certification for primary packaging materials (pharma GMP reference for packaging suppliers).
● structured change control, deviation handling, CAPA, training records.
Ema Pharma reports maintaining ISO 15378 certification since 2015 and conducting regular customer audits (over 20 audits between 2021 and 2023), with quality contracts and formal scoring in place with major contractors.
B. Controlled environment for assembly and final packaging
For caps supplied into cleanroom filling areas, the environment around assembly and packaging matters.
Ema Pharma describes:
● assembly and final packaging in an ISO 8 clean room / ISO 8-like environment (depending on the presentation format),
● monitoring of particle and bioburden contamination for its Clean Caps ranges.
C. In-process inspection and defect prevention
Ask how defects are detected and contained:
● inline camera inspection parameters (scratches, dents, ovality, inclusions, welding defects, dirt/particles),
● controls that reduce mix-ups (color, format, line clearance logic).
Ema Pharma highlights automated vision control and inspection through camera systems to detect color, dimensions, deformation, scratches, and inclusions.
D. Sterilization path: bulk vs RTS vs RTU
Your filling strategy dictates the format:
● Bulk caps: used when capping is performed outside an aseptic core with an appropriate protection strategy.
● RTS: supplied in packaging compatible with steam sterilization (Tyvek bags), supporting validated in-house cycles.
● RTU: gamma-sterilized, supplied with certificates, validated shelf-life, and packaging integrity confirmation.
Ema Pharma offers RTS and RTU finishes with controlled particle/bioburden expectations, along with validated processes for irradiated caps, including irradiation certificates.
E. Documentation you should expect per batch
A supplier qualified for injectables should support:
● Certificate of Conformity (COC) with each delivery,
● optional Certificate of Analysis (COA) with dimensional/functional results and particle/bioburden levels where applicable
● irradiation certificate for RTU supply.
Ema Pharma states systematic COC supply and COA available on request.
5) Ema Pharma capabilities that matter for injectable drug manufacturers
A. A French manufacturing base with scale
Ema Pharma presents:
● over 90 years of experience,
● installed annual capacity above 1.3 billion caps,
● global supply footprint serving pharma production sites across more than 40 countries.
B. Product range aligned with vial standards and user needs
Ema Pharma produces aluminum caps and aluminum/plastic caps in common vial neck sizes (11, 13, 20, 32, 42 mm, depending on product family) and designs, including:
● center hole,
● center tab,
● complete tear-off,
● push-off/flip-off formats for access protection and tamper evidence.
C. Packaging options for cleanroom transfer
Packaging choice is not a detail. It increases the risk of contamination during transfer and setup.
Ema Pharma lists packaging options such as:
● single PE bags,
● autoclavable Tyvek® bags (steam sterilization),
● double or triple PE bags (gamma-sterilized RTU supply),
● RTP bags for direct introduction into isolators (validated with equipment partners).
D. Technical assistance around crimping
Crimping is where seal design meets line reality.
Ema Pharma describes support services, including:
● machine settings and fine tuning for machinability,
● specific tool developments,
● container closure integrity (CCI) tests and technical assistance.
This support is valuable during:
● line transfers to a CMO,
● scale-up from clinical to commercial,
● capping station moves (inside/outside aseptic core),
● introduction of RTU caps in RABS/isolators.
E. Annex 1, lyophilization, and why RTU caps keep expanding
Lyophilization adds exposure time and handling steps. Annex 1 calls out that partially stoppered vials should be maintained under Grade A conditions, and that capping should follow stoppering as soon as possible.
Ema Pharma shares a customer case of a lyophilization line under RABS using RTU push-off caps, with stopper height controlled by camera and crimping under Grade A air supply. This is a clear picture of the direction many sites are taking.
F. Sustainability actions tied to manufacturing reality
For procurement and ESG programs, actions matter more than slogans.
Ema Pharma reports a sustainability journey that includes:
● removal of toxic production materials,
● waste reduction,
● energy actions,
● a move toward eliminating the degreasing step of aluminum caps (reduction of solvent use).
5) Quick FAQ for buyers, QA, and technical teams
Does the aluminum seal touch the drug product?
No. The seal does not come into contact with the drug product, unlike the elastomeric stopper. Still, it influences CCI by locking stopper compression and protecting the access area after crimping.
When should I move from bulk to RTS or RTU?
Common triggers:
● capping performed inside an aseptic core,
● isolator/RABS operation with reduced interventions,
● higher expectations on particle and bioburden control at point of use,
● new Annex 1 contamination control strategy updates.
What documents should I request for RTU caps?
At minimum:
● COC for each batch,
● irradiation certificate,
● COA if you require dimensional/functional or cleanliness data.
6) What to ask your supplier during an RFI
1. Which cap designs and skirt geometries do you recommend for our vial type (ISO/DIN) and line speed?
2. Which finish matches our capping location (bulk vs RTS vs RTU vs RTP)?
3. What are your in-process controls (camera inspection scope, frequency, reaction plan)?
4. Which certificates are standard vs optional (COC, COA, irradiation certificate)?
5. What change notification timelines do you support (materials, lacquer, tooling, packaging)?
6. What is your audit cycle, and how do you support customer audits?